Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
1. A pharmaceutical composition for treating an abnormal skin condition in a human in need thereof, comprising (a) a cell culture composition comprising a bacterial strain selected from Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc , or Oenococcus , and mixtures thereof, wherein the cell culture composition is a living cell culture composition, and wherein the cell culture composition comprises at least one engineered bacterial strain that produces a therapeutically effective amount of a recombinant polypeptide for treating the abnormal skin condition and (b) a pharmaceutically acceptable carrier.
2. A composition according to claim 1 wherein said composition comprises a bacterial strain containing human target DNA recombined with bacterial DNA.
3. A composition according to 1 , wherein the composition comprises an engineered strain of Staphylococcus epidermidis.
4. A composition according to claim 1 , wherein the pharmaceutically acceptable carrier comprises 0% water to no more than about 90% water.
5. A composition according to claim 1 , wherein the pharmaceutically acceptable carrier is selected from an aqueous solution, an emulsion, a cream, a lotion, a gel, or an ointment.
6. A pharmaceutical composition for treating an abnormal skin condition in a human in need thereof, comprising (I) a cell culture composition comprising a bacterial strain selected from Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc , or Oenococcus , and mixtures thereof, wherein the cell culture composition is a living cell culture composition, and wherein the cell culture composition comprises at least one engineered bacterial strain that produces a therapeutically effective amount of a recombinant polypeptide comprising (a) a filaggrin amino acid sequence, (b) a secretion signal, and (c) a cell penetrating peptide and (II) a pharmaceutically acceptable carrier, for treating the abnormal skin condition.
7. A composition according to claim 6 wherein said composition comprises a bacterial strain containing human target DNA recombined with bacterial DNA.
8. A pharmaceutical composition according to 6 , wherein the cell culture composition comprises Staphylococcus epidermidis.
9. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence comprises a sequence selected from SEQ ID NO 1, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, or SEQ ID NO 17, and combinations thereof.
10. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence comprises SEQ ID NO 1.
11. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence has at least about 75% homology to SEQ ID NO 1.
12. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence has at least about 80% homology to SEQ ID NO 1.
13. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence has at least about 85% homology to SEQ ID NO 1.
14. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence has at least about 90% homology to SEQ ID NO 1.
15. A pharmaceutical composition according to claim 6 , wherein the filaggrin amino acid sequence has at least about 95% homology to SEQ ID NO 1.
16. A composition according to claim 6 , wherein the pharmaceutically acceptable carrier comprises 0% water to no more than about 90% water.
17. A composition according to claim 6 , wherein the pharmaceutically acceptable carrier is selected from an aqueous solution, an emulsion, a cream, a lotion, a gel, or an ointment.